The Globe and Mail reports in its Friday edition that RBC'S Douglas Miehm has reiterated his "outperform" recommendation for Knight Therapeutics. The Globe's David Leeder writes that Mr. Miehm gave his share target a 50-cent boost to $7. Analysts on average target the shares at $6.64. Mr. Miehm says in a note: "We view Knight's Q4/23 report as mixed, with revenues and adjusted EBITDA below estimates but FY24 guidance better than expected. Knight introduced 2024 guidance that was 3 per cent ahead of consensus revenues and 2.5 per cent above consensus adjusted EBITDA at the midpoint of the guidance range. The company signed a new contract with the MOH in Brazil for Ambisome, which is expected to generate $18.9-million in 2024 revenues (vs. $25.2-million in 2023 and $7-million in 2022). We continue to view Knight as a good long-term investment." The Globe reported on Sept. 24, 2021, that Stifel had upgraded Knight to "buy" from "hold." It was then worth $5.46. The Globe reported on March 28, 2023, that National Bank had lowered Knight to "sector perform" from "outperform." It was then worth $4.35. The Globe reported on March 7, 2024, that Raymond James continued to rate Knight "outperform." It was then worth $5.51.